Pharmaceuticals & Therapeutics

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

Beyond the active ingredient, a silent revolution in formulation technology is unlocking new frontiers in health, from clean labels to personalized nutrition.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

OSE Immunotherapeutics is taking back a key drug from AbbVie, betting its own cash on a bigger prize. What does this strategic pivot reveal about pharma R&D?

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

Immunome is using strategic stock grants to lure top talent. We analyze why this move is critical for its pipeline and what it means for investors.

A last-minute regulatory filing by Balyasny Asset Management pulls back the curtain on the multi-billion-dollar battle for Spectris, a key health tech enabler.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.